Massive dengue vaccine rollout under the microscope: 800,000 recipients analyzed
NCT ID NCT07501793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviews the records of up to 800,000 people who received the TAK-003 (Qdenga) dengue vaccine at VNVC centers in Vietnam between September 2024 and September 2025. Researchers will look at age, sex, location, and vaccination history to see who got the vaccine and how. No new tests or contact with participants is involved—only existing data is used.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-003 (Qdenga) dengue vaccine
What this could lead to
If successful, this study could help public health officials understand who is getting the dengue vaccine and how to improve vaccination campaigns in Vietnam.
What could go wrong
This is an observational study using existing records, so it cannot prove the vaccine's effectiveness or safety. It only describes who got vaccinated, not why or what happened afterward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENGUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vietnam Vaccine Joint Stock Company
Ho Chi Minh City, Ho Chi Minh, 700000, Vietnam